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Abstract
Diagnosis of visceral leishmaniasis (VL) relies on invasive and risky aspirate procedures,
and confirmation of cure after treatment is unreliable. Detection of Leishmania donovani
antigens in urine has the potential to provide both a non-invasive diagnostic and a test of
cure. We searched for L. donovani antigens in urine of VL patients from India and Sudan to
contribute to the development of urine antigen capture immunoassays. VL urine samples
were incubated with immobilised anti-L. donovani polyclonal antibodies and captured mate-
rial was eluted. Sudanese eluted material and concentrated VL urine were analysed by
western blot. Immunocaptured and immunoreactive material from Indian and Sudanese
urine was submitted to mass spectrometry for protein identification. We identified six L.
donovani proteins from VL urine. Named proteins were 40S ribosomal protein S9, kinases,
and others were hypothetical. Thirty-three epitope regions were predicted with high specific-
ity in the 6 proteins. Of these, 20 were highly specific to Leishmania spp. and are highly suit-
able for raising antibodies for the subsequent development of an antigen capture assay. We
present all the identified proteins and analysed epitope regions in full so that they may con-
tribute to the development of non-invasive immunoassays for this deadly disease.
Introduction
Visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in the Indian
subcontinent and eastern Africa, whereas L. infantum is the agent in the Mediterranean, Mid-
dle East and South America. Both species are transmitted by female phlebotomine sand flies
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and symptomatic infection is considered fatal if untreated, therefore accurate diagnosis is cru-
cial to patient outcome. India, Bangladesh and Nepal are aiming to eliminate VL as a public
health problem and this relies on rapid case detection and confirmation of cure after treatment
[1].
Routine diagnosis of VL is based on serology, commonly using the recombinant rK39 or
rK28 antigens, followed by microscopic visualisation of the parasite in spleen, bone marrow or
lymph node aspirate as confirmation. Conventional serology, which detects anti-Leishmania
IgG, has several drawbacks: it is ineffective at confirming cure or relapse because it can remain
positive for many years after successful treatment [2–6]; it is also less reliable in HIV co-
infected cases where a negative result does not rule out leishmaniasis [7]. Molecular assays are
sometimes applied, and may gain increased importance during VL elimination, however, non-
invasive antigen detection would complement this as a diagnostic tool [8].
An ideal diagnostic for both primary VL cases and validating cure is the detection of para-
site material in non-invasive samples such as urine or saliva, or a serological test that is specific
for active infection [9]. As well, there is the need for low-cost, rapid and equipment-free diag-
nostics that can be used in low-resource settings at point-of-care with minimal training. Such
assays may detect parasite DNA, for example by loop-mediated isothermal amplification
(LAMP) [10, 11] or by recombinase polymerase amplification (RPA) [12], or may detect para-
site antigens.
Several urine antigen capture immunoassays have been developed with the best established
being the KAtex, a latex particle agglutination test that detects a carbohydrate antigen [13, 14].
The KAtex has a specificity of 84–100%, but poorer sensitivity of 47–87% [15–18] with the
drawback that urine samples must be boiled before testing. However, the test is rapid, giving a
result in less than 10 minutes and becoming negative for most patients 30 days post-treatment
[18]. In addition, this urine antigen assay has shown utility in HIV/VL co-infection [19, 20].
Monoclonal and polyclonal antibodies against the undefined antigen in the KAtex test were
later adapted to ELISA format [21].
Other assays have been reported that detect particular protein antigens of L. infantum in
urine [22]. This approach required first identifying Leishmania proteins in VL urine by mass
spectrometry, expressing them as recombinant antigens and raising antibodies that could be
produced as highly specific and sensitive polyclonal or monoclonal antibodies [22].
An alternative approach is to raise antibodies to lysed whole parasite cells, containing a
wide diversity of antigens and to use these to capture a range of undefined antigens from VL
patient urine. Vallur et al. [23] reported the development of an ELISA using an affinity purified
polyclonal rabbit antibody against L. donovani whole cell lysate. The assay was optimised by
those authors and developed into an ELISA kit that performed well in detecting urine antigen
in VL patients from both L. infantum and L. donovani endemic regions. Here we have under-
taken a study using this antibody and other polyclonal anti-Leishmania antibodies, and by
mass spectrometry, we have identified antigens in Indian and Sudanese VL urine, for the
development of antigen capture assays.
Materials and methods
Ethics statement
Ethical permission was granted by the LSHTM Ethical Review Committee with approval num-
ber 11478, and as part of the EC-funded NIDIAG project. In India, the collection of samples
was approved by the Ethics Committee of Banaras Hindu University, Varanasi. In Sudan,
approval was by the Ethical Research Committee, Faculty of Medicine, University of Khar-
toum and the National Health Research Ethics Committee, Federal Ministry of Health, Sudan.
PLOS ONE Leishmania antigens in visceral leishmaniasis urine
PLOS ONE | https://doi.org/10.1371/journal.pone.0238840 September 14, 2020 2 / 16
partnership supported by the European
Commission under the Health Cooperation Work
Programme of the 7th Framework Programme
(Grant agreement no. 260260, https://cordis.
europa.eu/project/id/260260). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Written informed consent was obtained from adult subjects included in the study or from the
parents or guardians of individuals less than 18 years of age.
Two rabbits were used here to raise antiserum. Rabbit sera were produced in compliance
with UK Home Office regulations and the Animals (Scientific Procedures) Act 1986, in autho-
rised animal facilities, by licensed staff, and in accord with European regulations and the 3R
policy of Refinement, Reduction and Replacement.
Processing and analysis of samples
Fig 1 depicts the overall workflow of the urine samples in this study. We used two distinct
methods in order to maximise the possibility of antigen capture.
Urine samples
Urine samples were from VL patients and healthy controls in two distinct VL endemic regions,
namely the Indian state of Bihar and the Sudanese state of Gedaref. India: urine samples were
collected from VL patients attending the Kala-Azar Medical Research Centre (KAMRC) clinic
in Muzaffarpur, Bihar. Sudan: VL and endemic healthy control (EHC) urine samples were col-
lected from field sites in Gedaref. In this work Leishmania-derived antigens were enriched
from VL urine using antibodies, prior to mass spectrometry.
Generation of rabbit anti-L. donovani antibodies
Vallur et al. [23] described the generation of a rabbit anti-L. donovani polyclonal antibody
against whole promastigote lysate antigen, which was affinity purified against soluble promas-
tigote lysate antigen of L. donovani strain MHOM/SD/00/1S-2D. This antibody is hereafter
referred to as anti-1S2D.
Here, we prepared soluble promastigote lysate antigens of L. donovani strains MHOM/IN/
80/DD8 and MHOM/ET/67/LV9 (also known as HU3), as described [24]. Log phase promasti-
gotes were washed 3 times in PBS, pelleted by centrifugation, flash frozen in liquid nitrogen
and thawed 3 times, sonicated (Soniprep 150, MSE, UK) at 12 microns intensity for 3 x 30 sec-
onds at 2-minute intervals on ice and finally centrifuged at 12,000 x g for 1 minute at 4˚C. The
supernatants containing soluble antigens were retained and used subsequently.
Soluble antigen (DD8 and LV9) was used to raise antiserum in two rabbits that were immu-
nised percutaneously with two doses of the respective lysate. The first inoculation was with
200 μg—500 μg of lysate antigen (originating from approximately 107 parasites) with Freund’s
complete adjuvant (F5881, Sigma-Aldrich). A second inoculation, four weeks later, was with
the same amount of antigen, plus Freund’s incomplete adjuvant (F5506, Sigma-Aldrich). Five
millilitres of blood was taken before inoculations and about 50 ml five months after the second
inoculation.
The resulting polyclonal IgG was purified from both DD8 and LV9 antisera on protein A
agarose (P3476, Sigma, UK), eluted with 0.1 M glycine, pH 2.7 and immediately neutralised
with 60 μl of 1 M Tris pH 9.0. The purified IgG elutions are hereafter referred to as anti-DD8
and anti-LV9. An ELISA was performed to confirm the reactivity of the two antibodies with L.
donovani antigen and that the pre-immune sera were non-reactive.
Indian VL urine
Precipitation of urine proteins. Total protein was precipitated from Indian VL patient
urine: approximately 130 ml of urine (83 ml fresh and 52 ml previously frozen) was combined
from 31 Indian VL patients and protease inhibitor cocktail (P8340, Sigma-Aldrich) was added
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Fig 1. Sample processing and analysis workflow used in this study. Asterisks indicate immunocapture methods. Anti-1S2D, -DD8 and
-LV9 are rabbit antibodies against these respective strains of L. donovani. VLu, concentrated proteins from VL urine; EHCu, concentrated
proteins from urine of Endemic Healthy Controls; uAg, material captured from VL urine by anti-L. donovani antibodies; LC-MS/MS,
liquid chromatography tandem mass spectrometry.
https://doi.org/10.1371/journal.pone.0238840.g001
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at a dilution of 1:500. The urine was centrifuged at 2,500 x g for 3 minutes to pellet cellular
debris, which was discarded. To the supernatant, we added 85 g solid ammonium sulphate to
achieve 90% saturation then incubated the solution for one hour at ambient temperature
(about 28˚C) with mixing to allow proteins to precipitate. The urine/ammonium sulphate
solution was centrifuged in aliquots at 3,900 x g at 20˚C for 40 minutes and the supernatant
was discarded. Protein pellets were then resuspended as two aliquots in a total of 4.25 ml PBS
then desalted using PD10 columns (170851–01, GE Healthcare) by the centrifugation protocol
and each replicate made up to 3 ml with PBS.
Immunocapture of proteins. To capture L. donovani antigens from the precipitated
Indian VL urine protein, we performed immuno-panning (Fig 1, upper left). Anti-1S2D anti-
body was coated onto 5 cm diameter plastic dishes at 8 μg/ml (Dish 8) and, to increase antigen
capture, at 35 μg/ml (Dish 35) in 1.5 ml coating buffer (0.1 M NaHCO3, pH 8.6) by incubation
at 4˚C overnight. The unbound antibody was removed, replaced with blocking buffer (coating
buffer containing 5 mg/ml bovine serum albumin) and the dishes were incubated at 4˚C for 1
hour. After blocking, both dishes were washed 5 times using PBS containing 0.05% v/v Tween
20 (PBST), with gentle agitation.
The first aliquot of urine protein solution was incubated in Dish 8 for 1 hour at room tem-
perature with agitation before the unbound material was moved into Dish 35. Dish 8 was
washed 3 times with PBST then another 3 times with PBS before bound material was eluted
with a 15 minute incubation with 1 ml of 0.1 M glycine pH 2.7. Eluate was pipetted into a tube
containing 32 μl neutralising buffer (1 M Tris pH 9.0) and sodium azide to a final concentra-
tion of 0.02% (w/v) then stored at -80˚C.
Unbound material from Dish 35 was transferred back to Dish 8 for repetition of the whole
process. From each of the two aliquots of urine protein solution, two elutions were made from
each of the two dishes (thus n = 8 eluates), to maximise the chance of capturing Leishmania
antigens. After each elution, the dishes were washed 10 times with PBS prior to re-use.
Eluates containing captured proteins were pooled into two volumes: one from Dish 8, the
other from Dish 35. These were buffer exchanged into PBS and spin concentrated at 5˚C in 3
kDa molecular weight cut-off (MWCO) Amicon Ultra filters (UFC500324, Millipore) at
14,000 x g in several 20 minute spins until the total volume of each was reduced to 100 μl.
Sudanese VL urine
Concentration of urine proteins. Sudanese VL patients’ urine from seven individuals
was pooled, 0.4 ml from each to give 2.8 ml, and spin concentrated to 190 μl in Amicon Ultra 3
kDa MWCO tubes, with a final protein concentration of 12.5 mg/ml (hereafter ‘VLu’ for VL
urine). Pooled EHC urine, 0.5 ml each from 14 individuals, was spin concentrated as above,
down to about 100 μl (EHCu). Both urine concentrates were then washed to remove salts by
making up to 0.5 ml with PBS and spinning down five times. These two concentrates, VLu and
EHCu, were run in SDS-PAGE as described further below (Fig 1, upper right).
Affinity chromatography. Separately, another pool of Sudanese VL urine comprising 0.5
ml each of 57 individual urines with 1/100 protease inhibitor (P8340, Sigma-Aldrich) was con-
centrated with a ProteoSpin Urine Protein Concentration Micro Kit (17400, Norgen Biotek
Corp) as per manufacturer’s instructions and in batches to avoid overloading the capacity of
the kit to a final volume of 3.7 ml. To capture L. donovani antigens in urine, rabbit anti-DD8
was coupled to a cyanogen bromide-activated Sepharose matrix (C9142, Sigma-Aldrich) fol-
lowing manufacturer’s instructions and the 1.75 ml of gel was loaded into a disposable column.
Due to limited amounts of anti-LV9 and anti-1S2D antibodies, anti DD8 was used for chroma-
tography. The column was equilibrated using ten column volumes of PBS prior to use. Urine
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protein concentrate was incubated on the anti-DD8 column for 10 minutes, drained, washed 3
times with 10 ml PBS and bound material was eluted in 8 x 1 ml volumes of 0.1 M glycine pH
2.7, neutralised with 32 μl neutralising buffer per 1 ml eluate. Eluted fractions indicated to con-
tain antigen by a dot blot were spin concentrated to give ‘VL urine antigen (uAg)’. Briefly, the
dot blot consisted of 2 μl of each fraction dried onto nitrocellulose, blocked with PBS + 3% w/v
non-fat milk powder (Premier International Foods, Spalding, UK) (PBSM), probed with anti-
DD8 and detected with anti-rabbit IgG-horseradish peroxidase (HRP) (711-035-152, Jackson
Immunoresearch) and DAB/CN substrate, with details as described below.
SDS-PAGE and western blotting. Both of the Sudanese VL urine products, namely the
urine concentrate (VLu) and immune-selected urine antigen (uAg), were subjected to non-
reducing SDS-PAGE in duplicate lanes of a 10% acrylamide Tricine gel as described by Schäg-
ger [25]. Half of the gel was stained firstly for carbohydrate using Pro Q Emerald 300 (P21857,
ThermoFisher Scientific) visualised at 280 nm (Gel Doc, ThermoFisher Scientific) then the
same gel was stained for protein using Sypro Ruby (S12000, ThermoFisher Scientific) and visu-
alised with 488 nm excitation and 610 nm emission wavelengths (Typhoon Trio phosphorima-
ger, Amersham Biosciences).
The other identical gel half was transferred onto 0.2 μm pore size nitrocellulose (10600015,
GE Healthcare) at 160 mA for 120 minutes and air-dried. The membrane was then blocked
using PBSM overnight at 4˚C then washed in PBST, three times for 10 min each. Rabbit anti-
DD8 and anti-LV9 were conjugated to HRP using a Lightning Link kit (701–0000, Expedeon)
then diluted together at 1:400 and 1:500 respectively in PBST + 3% milk powder (PBSTM) and
incubated on the blot for 2 hours with gentle agitation. The membrane was washed with PBST
six times for 5 minutes each before addition of DAB/CN substrate solution (30 μg 4-chloro-
1-naphthol dissolved in 5 ml methanol then added to 40 ml PBS, followed by the addition of
10 μg of 3,3’-diaminobenzidine dissolved in 5 ml methanol and finally 15 μl of 30% H2O2).
The blot was incubated for 15 mins with gentle agitation in the dark before stopping the reac-
tion by washing in deionised water several times.
Due to limited signal gained from these rabbit polyclonals conjugated directly to HRP, the
blot was stripped using stripping buffer (0.2 M glycine, 0.1% SDS, 1% Tween 20, pH 2.2) for 10
min with agitation, followed by 2 x 10 min washes in PBS and 2 x 5 min washes in Tris buff-
ered saline with Tween (20 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.6) (TBST). After
stripping away the previous reaction, the blot was re-blocked and probed with the same two
rabbit anti-L. donovani antibodies without HRP conjugation, followed by anti-rabbit IgG-HRP
at 1:1000 and DAB/CN substrate as before. Bands in the carbohydrate/protein-stained gel half,
corresponding to immunoreactive blot bands in the two VL urine sample types, were excised
for mass spectrometry.
Mass spectrometry
The excised gel bands from Sudanese VLu and uAg, as well as the two Indian VL urine eluates
from the panning dishes, were submitted to trypsin digest and liquid chromatography tandem
mass spectrometry (LC-MS/MS) at the Advanced Proteomics Facility, Oxford University, UK.
For all samples, mass spectra were assigned to L. donovani peptides by a simultaneous
search using Mascot (Matrix Science, UK) against both the L. donovani BPK282A1 reference
[26] and UniProt Homo sapiens protein databases, which contained all the proteins of these
organisms, as deduced from their genomes [27]. Criteria for identifying Leishmania peptides
were being rank 1 (the peptide with the best match for a particular mass spectrum) and having
a ppm of -10 to 10 (error on experimental peptide mass values, fraction expressed as parts per
million). Proteins were identified when they contained 2 or more different peptides matching
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the above criteria and were taken forward to further analysis (Fig 1, lower panel). Once identi-
fied, peptides and proteins from VLu and uAg from Sudanese samples were considered
together for subsequent analysis of their properties, as detailed below.
Epitope prediction
Epitope prediction was carried out to indicate short, Leishmania-specific peptides within the
identified proteins that may be more easily synthesised for proceeding with antibody genera-
tion and test development. The complete amino acid sequences of proteins identified by 2 or
more peptides were obtained through UniProtKB [27] and submitted to B-cell epitope predic-
tion by BepiPred 2.0 [28]. The epitope score threshold was set at 0.65 (on a scale of 0 to 1),
which gave a specificity of 99% and sensitivity of 2%, with an alternative threshold of 0.55 for
higher sensitivity (specificity 81.6%, sensitivity 29%). Minimum length was 8 residues, with no
maximum.
Specificity of proteins and epitopes to L. donovani
Specificity of the mass spectrometry-identified peptides to Leishmania was ensured by a simul-
taneous search of the data against both human and Leishmania proteomes, with only those
matching to Leishmania being taken forward to ensure that they were not chance matches to
human peptides. This was followed by sequence analysis to confirm genus specificity. Proteins,
and predicted epitope peptides from these proteins, were assessed for sequence similarity to
other species using a BLASTP search against the NCBI non-redundant (nr) database with no
species restriction and using the default settings. For epitope sequences, the BLASTP search
was optimised for short sequences. BLAST output was assessed for the sequence identity
between the query and biologically-relevant species, i.e., human pathogens and commensals.
Sequence similarity to other Leishmania species was tolerated if L. donovani was a complete
match.
Signal peptide prediction
Proteins were submitted to SignalP 4.1 [29] to predict the presence of a signal peptide, which
provided evidence that the protein may be secreted from the cell by this method, although
Leishmania also has other secretory pathways. SignalP 4.1 is optimised to distinguish between
transmembrane domains and signal peptides [29].
Glycosylation prediction
N-linked glycosylation of proteins was predicted using NetNGlyc [30], which identified poten-
tial glycosylation sites via the R-group nitrogen atom of asparagine in the Asn-X-Ser/Thr
motif, where X could be any amino acid residue except Pro. Glycosylation could indicate that
the protein sequence underlying the glycan is inaccessible to capture antibodies, or that the
glycan itself could be investigated as a diagnostic antigen.
Protein properties
The possible identities of hypothetical proteins identified by mass spectrometry were sought
using online tools that identify domains and protein features based on sequence similarity
with known proteins: NCBI domain enhanced lookup time (DELTA) BLAST tool [31]; Inter-
Pro [32]; BlastKOALA (KEGG Orthology and Links Annotation) via KEGG [33]. Additional
information on protein features was from Expasy Prosite [34] and published literature.
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Results
Using mass spectrometry, we identified four L. donovani proteins in Indian VL urine and two
in Sudanese VL urine. Epitope prediction returned 33 B-cell epitopes of 8 or more amino
acids, within the complete protein sequences of the 6 proteins. Of the 33, 20 had complete
identity only with Leishmania spp. in a BLAST search of the NCBI nr database of all organ-
isms. Details of peptides and proteins from each urine source are described further below. Full
protein sequences, annotated with the detected peptides and predicted epitopes, are shown in
S1 Fig.
Indian VL urine antigen capture
In total from Indian VL urine, 19 different peptides were identified as those of L. donovani
after a search of the mass spectra against L. donovani and human protein databases simulta-
neously; 11 and 12 from each panning dish respectively, with four present in both dish eluates
(S1 Table).
Four proteins, one of which occurred on both panning dishes, were confidently identified
by more than one peptide (Table 1). In addition to proteins, 10 solo peptides (i.e., the only rep-
resentatives of their parent protein) were identified with a highly reliable ID by mass spectrom-
etry and high specificity to L. donovani (S2 Table).
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Hypothetical protein (LdBPK_160110 /
XP_003859699.1)
VRFRPNASLADGDAKSSAHGTVTQYGSPA‡ [29]





VLu: concentrated proteins from VL patient urine; aa: amino acid.
‡ This peptide was identified by the lower epitope score threshold of 0.55 because the protein did not contain epitopes>8 residues at a threshold of 0.65.
https://doi.org/10.1371/journal.pone.0238840.t001
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Sudanese VL urine antigen capture
L. donovani peptides and proteins were identified by mass spectrometry of excised gel bands
corresponding to immunocaptured urine antigen (uAg) and immunoreactive VL urine com-
ponents (VLu) (Fig 2). Protein and carbohydrate staining of the SDS PAGE gel revealed that
very few of these antigens were glycoproteins (Fig 2B and 2C).
Mass spectrometry of the Sudanese VL urine material (uAg and VLu) excised from the SDS
PAGE gel confidently (>1 peptide) identified two proteins and nine additional solo peptides
(Table 1 and S2 Table). The peptides with a confident mass spectrometry ID had complete
identity only to proteins from Leishmania genus according to a BLAST search, but part of
some sequences occurred in other human pathogens or commensals. Specificity to Leishmania
was improved when two peptides from the same protein were considered together.
Specificity of proteins to L. donovani
In total, we identified six proteins with confidence (>1 peptide) from Indian (4 proteins) and
Sudanese (2 proteins) VL urine that showed high specificity to Leishmania spp., although not
necessarily to L. donovani (Table 1). From Indian VL urine, protein kinase (LdBPK_262110)
and hypothetical proteins (LdBPK_191140, LdBPK_323250) showed very high sequence simi-
larity to several Leishmania species including L. infantum and species causing cutaneous leish-
maniasis, and moderate identity to Trypanosoma cruzi proteins. The 40S ribosomal protein S9
(LdBPK_070760) also had high sequence identity to that of other Leishmania species, but little
to any other genera.
The two L. donovani proteins identified in Sudanese VL urine, hypothetical protein
(LdBPK_160110) and protein kinase (LdBPK_351070), also had very high homology to L.
infantum with minor sequence differences between these and other Leishmania species. Mod-
erate homology was found between the hypothetical protein and those of T. cruzi, whereas the
protein kinase had high homology with T. cruzi proteins.
In addition to the proteins, 19 solo peptides were identified in total by all methods, 10 from
Indian and 9 from Sudanese VL urine (S2 Table). Seven of these were from named proteins
and all others were from hypothetical proteins. Interestingly, there was no overlap between L.
donovani peptides from Indian and Sudanese VL urine.
Epitope prediction
All 6 Leishmania proteins identified in the Indian and Sudanese VL urine were submitted to
epitope prediction using BepiPred 2.0 and together contained 33 peptides at a score threshold
of 0.65 which optimised specificity and 119 epitopes at a threshold score of 0.55, which pro-
vided higher sensitivity (S3 Table). None of the 6 proteins contained signal peptides and 4 con-
tained potential N-linked glycosylation sites (S3 Table).
Potential VL urine antigens
The 33 epitope peptides predicted with high specificity within the identified Leishmania pro-
teins, and one additional with lower specificity, were assessed for specificity to L. donovani.
Twenty of the 34 epitope sequences were selected as they had complete sequence identity to L.
donovani and little or no identity to sequences from other relevant species i.e., human patho-
gens or commensals. Specific peptides or possible epitope regions indicated for production of
antibodies for use in antigen capture assays are detailed in Table 1.
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Discussion
Validated tests for urine antigen in infectious diseases include those for schistosomiasis [35],
tuberculosis [36], Legionella pneumophila and Streptococcus pneumoniae [37], among others.
Fig 2. Sudanese VL patients’ urine (VLu) and immunocaptured urine antigen (uAg) detected by rabbit anti-L. donovani DD8 and -LV9 by
western blot. Regions submitted to mass spectrometry are broadly indicated by boxes. A) western blot, B) corresponding gel stained for proteins, C)
the same gel as B, stained for carbohydrates. Molecular mass marker (M) sizes in kiloDaltons. Lanes are: lysate antigen of L. donovani strain DD8; uAg,
VL urine material eluted from an anti-L. donovani DD8 immunochromatography column; VLu, concentrated VL urine; EHCu, concentrated urine
from endemic healthy controls. Vertical lines indicate where the photographs were spliced to remove non-relevant lanes from the original images, and
realigned based on the molecular weight marker.
https://doi.org/10.1371/journal.pone.0238840.g002
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Here, we captured L. donovani antigens from VL patient urine by two methods using immobi-
lised anti-L. donovani antibodies in panning and chromatography. Both methods yielded para-
site peptides which we identified by mass spectrometry. These led to identification of six L.
donovani proteins from urine of VL patients from India and Sudan. The proteins were pre-
dicted to contain highly species-specific epitopes that therefore make good candidates for tar-
gets of a non-invasive urine antigen capture immunoassay for VL. We additionally identified
19 single peptides with very high identity to L. donovani, which provide evidence of additional
parasite proteins in VL urine.
Studies using similar methods to identify pathogen antigens in urine include those of Abei-
jon et al. [22, 38] who identified L. infantum proteins tryparedoxin peroxidase, superoxide dis-
mutase and nuclear transport factor 2, by mass spectrometry of concentrated Brazilian VL
urine excised from gel bands, as well as L. donovani proteins encoded by genes Ld-mao1, Ld-
ppi1, Ld-clp1 and Ld-mad1 from Indian and Kenyan VL urine. We did not identify any of
these proteins, and in addition, none of the peptides and proteins that we found occurred in
both Indian and Sudanese samples. This suggests that there could be many proteins or protein
fragments of parasite origin in the urine of VL patients. However, differences between the
studies were that we used an antibody (1S2D) to capture antigens while other studies did not.
We searched mass results against a single genome database to identify peptides, which may
have limited our findings, whereas Abeijon et al used a wide range of genomes [38]. However,
we performed a rigorous quality control in order to exclude false peptide matches to Leish-
mania of peptides that were actually of human origin.
The proteins identified here are likely to be intracellular, based on their identities and fea-
tures. However, Leishmania has various secretion pathways, therefore the proteins may be
secreted by non-classical mechanisms [39]. Four proteins did contain potential glycosylation
sites, a feature more common to surface proteins involved directly in host-parasite interactions
[40, 41]. The carbohydrate and protein staining of the SDS-PAGE gel also indicated that very
few proteins were glycosylated, and those that were, were not detected by antibodies on the
corresponding blot. This may be expected as the rabbit antibodies were raised against a soluble
lysate antigen from a preparation method that favours intracellular contents rather than cell
membranes. By comparison, the KAtex assay that detects a carbohydrate antigen uses an anti-
body raised against whole intact parasites [13].
Three of the 6 proteins identified in VL urine were hypothetical proteins, defined by the
presence of start and stop codons in their genomic sequences but without experimental evi-
dence for the protein itself. These proteins were submitted to several protein domain identifi-
cation tools to reveal possible similarities to well characterised proteins and elucidate their
features and possible functions in Leishmania (Table 2).
The great difference in western blot and SDS-PAGE gel profiles between the concentrated
Sudanese VL urine (VLu) and urine antigens (uAg) purified from the same sample type was
unexpected. However, the sensitivity of antibodies used may detect proteins that are not read-
ily visible on the gel. In addition, the process of stripping and re-probing the blot could have
somewhat altered the composition of the blot. However, the EHCu remained negative, indicat-
ing very little non-specific reaction. Heating the urine, which we did not do, could have led to
more specific reactions [42], however, this favours carbohydrate antigens as it denatures pro-
teins and we sought to retain as many of the conformational protein epitopes as possible by
running non-reduced samples on gels.
Coiled protein regions are often made by repeats of a few of the same amino acids, as identi-
fied here in hypothetical protein LdBPK_191140, and this repetition can lead to high antige-
nicity, making them good targets for immunodiagnostics [43–45]. The geographic overlap of
VL with Chagas disease, caused by T. cruzi, particularly in Brazil, makes it imperative to
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identify a Leishmania antigen that will not cross-react with this other trypanosomatid.
Although the proteins identified here had very high sequence identity with L. donovani or L.
infantum, some had moderate and one had high homology with T. cruzi proteins. Therefore, a
polyclonal antibody against a complete L. donovani protein could also react with T. cruzi pro-
teins. For this reason, as done here, selecting shorter and more species-specific peptide
sequences is preferable because these contain fewer epitopes and generate a more specific anti-
body response, although it is unclear whether these epitopes would be linear or
conformational.
Based on the species specificity of the epitope regions, we suggest that combining several of
these, either for raising a mixed polyclonal antiserum, or later combining individual antibodies
in the assay, may improve specificity and sensitivity of the prospective assay. This was found
by Abeijon et al. [22, 46] where combined assays had improved performance over individual
analyte assays.
A strength of our study was that the criteria for identifying parasite proteins in VL urine
took into account the large number and amount of human proteins in the sample [47]. Initial
steps to enrich for Leishmania antigens using specific antibodies assisted in achieving peptide
identification by mass spectrometry. Further, by searching mass data simultaneously against
both human and L. donovani protein databases, we were able to exclude mass spectra that had
a better match to human peptide sequences, thus excluding potential false positive matches to
L. donovani. The dual searching did not exclude possible matches to bacterial peptides, there-
fore we searched both the peptides and the proteins against the NCBI nr database to exclude
this possibility.
A potential limitation to our technique is that while we have presented L. donovani protein
identities here, there is no certainty that these proteins exist as whole proteins in VL urine as
we can only identify short peptides by mass spectrometry. However, the presence of the pep-
tides suggests that at least fragments of the proteins do occur in urine, along with many host-
derived proteins [47, 48]. We used a large volume of urine from multiple VL patients in order
to capture the peptides that were identified. However, with more abundant samples, it would
have been beneficial to conduct replicates to investigate the frequency of these peptides in VL
urine. Progression from identifying VL urinary antigens to having a prototype rapid diagnostic
test (RDT) relies on follow-up to synthesise antigens and raise antibodies. An alternative
method to develop monoclonal antibodies directly against precipitated urine proteins could
also be attempted, followed by screening for sensitivity and specificity for VL, as used for
malaria [49].






India LdBPK_191140a Predicted zinc finger RING-type domain;
predicted coil regions
Ubiquitination pathway and other intracellular protein processing pathways.
India LdBPK_323250a DENN domain Involved in GTP/GDP exchange and occur in other proteins that regulate
membrane traffic in eukaryotes.
India LdBPK_070760 40S ribosomal S9 protein Protein subunit of the 40S ribosomal subunit.
India LdBPK_262110 Protein kinase Add phosphate groups in cell signalling pathways.
Sudan LdBPK_351070 Protein kinase Add phosphate groups in cell signalling pathways.
Sudan LdBPK_160110a MORN repeat motif Unknown.
a hypothetical protein.
https://doi.org/10.1371/journal.pone.0238840.t002
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Conclusions
We used various methods to capture L. donovani antigens from VL urine from India and
Sudan, including panning of urine proteins with immobilised anti-L. donovani antibodies and
visualisation of immunoreactive bands in VL urine on a western blot. All methods yielded L.
donovani proteins by mass spectrometry of captured or immunoreactive material and 5 of 6
proteins were highly specific to Leishmania. In addition, epitope prediction revealed 20 Leish-
mania-specific B-cell epitopes that we present here, that make ideal candidates for synthesis
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